Showing results (961-970 of 1,192) with videos related to
Sort By:
Pageof 120
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.The Lancet. Haematology|April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort studyCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.Cancer|August 26, 2017
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignanciesYasmin M Abaza, Tapan M Kadia, Elias J Jabbour, et al.Leukemia & Lymphoma|July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemiaNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.Cancer|January 18, 2017
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromesGuillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, et al.Haematologica|February 20, 2025
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndromeIan M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.Blood|August 5, 2017
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPNElias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, et al.The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.Journal of Cutaneous Pathology|September 9, 2017
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemiaSanam Loghavi, Jonathan L Curry, Guillermo Garcia-Manero, et al.Pageof 120